{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:34:41Z","timestamp":1790872481117,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.vph.2006.08.012","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T17:49:01Z","timestamp":1156528141000},"page":"334-339","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic angiogenesis: Translating experimental concepts to medically relevant goals"],"prefix":"10.1016","volume":"45","author":[{"given":"Costanza","family":"Emanueli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2006.08.012_bib1","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1016\/S0002-9343(99)00011-X","article-title":"Neurotrophic factors in the therapy of diabetic neuropathy","volume":"107","author":"Apfel","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2006.08.012_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1172\/JCI200523669","article-title":"Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans","volume":"115","author":"Azizi","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2006.08.012_bib4","first-page":"584","article-title":"Polymorphism of kallikrein gene and abnormalities of the endothelial function","volume":"21","author":"Azizi","year":"2005","journal-title":"Med. Sci."},{"key":"10.1016\/j.vph.2006.08.012_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(99)02784-1","article-title":"Effect of topical application of nerve-growth factor on pressure ulcers","volume":"354","author":"Bernabei","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2006.08.012_bib6","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.ATV.20.12.2573","article-title":"Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization","volume":"20","author":"Chae","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2006.08.012_bib7","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/emboj\/21.8.1939","article-title":"Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy","volume":"21","author":"Dor","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.vph.2006.08.012_bib8","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/01.CIR.0000039342.85015.5C","article-title":"FrzA, a secreted frizzled related protein, induced angiogenic response","volume":"106","author":"Doufourq","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib9","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1101\/gad.914801","article-title":"Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha","volume":"15","author":"Elson","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.vph.2006.08.012_bib10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.ATV.20.11.2379","article-title":"Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle","volume":"20","author":"Emanueli","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2006.08.012_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.103.1.125","article-title":"Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia","volume":"103","author":"Emanueli","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib12","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1161\/01.CIR.0000033971.56802.C5","article-title":"Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs","volume":"106","author":"Emanueli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.0000142051.36244.83","article-title":"Akt\/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer","volume":"110","author":"Emanueli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nm905","article-title":"Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth","volume":"9","author":"Fahmy","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib15","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hc1102.105595","article-title":"Angiogenic GENe Therapy (AGENT) trial in patients with stable angina pectoris","volume":"105","author":"Grines","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib16","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/01.CIR.0000048183.37648.1A","article-title":"CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes","volume":"107","author":"Heeschen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archopht.123.4.509","article-title":"Safety and efficacy of intravitreal injection of ranibizumab in combination with veterporfin PDT on experimental choroidal neovascularization in the monkey","volume":"123","author":"Husain","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.vph.2006.08.012_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/72212","article-title":"Leaky vessels? Call Ang1!","volume":"6","author":"Jain","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt1117","article-title":"Regenerating the heart","volume":"23","author":"Laflamme","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.vph.2006.08.012_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7326\/0003-4819-139-8-200310210-00006","article-title":"Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial","volume":"139","author":"Landi","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1161\/01.CIR.0000128595.79378.FA","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part I. Angiogenic cytokines","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib24","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1161\/01.CIR.0000128596.49339.05","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II. Cell-based therapy","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib25","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(02)08937-7","article-title":"Therapeutic Angiogenesis with Recombinant Fibroblast growth Factor-2 for Intermittent Claudication (the TRAFFIC study): a randomised trial","volume":"359","author":"Lederman","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2006.08.012_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"Makinen","year":"2002","journal-title":"Molec. Ther."},{"key":"10.1016\/j.vph.2006.08.012_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/hc0102.101360","article-title":"Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia","volume":"105","author":"Porcu","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/01.ATV.0000128126.57688.a9","article-title":"Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis","volume":"24","author":"Porcu","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2006.08.012_bib29","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib30","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM200504213521619","article-title":"Pegaptanib and age-related macular degeneration","volume":"352","author":"Rakic","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nbt1101-1029","article-title":"Polymeric system for dual growth factor delivery","volume":"19","author":"Richardson","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.vph.2006.08.012_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1096\/fj.02-0377fje","article-title":"Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model","volume":"17","author":"Rissanen","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.vph.2006.08.012_bib33","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1161\/CIRCULATIONAHA.104.527135","article-title":"Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes results of three randomized studies","volume":"111","author":"Sandri","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.57.7.1313","article-title":"Long-term treatment with recombinant nerve growth factor HIV-associated sensory neuropathy","volume":"57","author":"Schifitto","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.vph.2006.08.012_bib35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/hc0802.104407","article-title":"Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor: 2. Double-blind, randomized, controlled clinical trial","volume":"105","author":"Simons","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib36","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1161\/01.STR.31.8.1863","article-title":"Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke","volume":"31","author":"Slevin","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2006.08.012_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.CIR.0000040999.00692.F3","volume":"106","author":"Stewart","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2006.08.012_bib38","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(00)03212-8","article-title":"NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis","volume":"356","author":"Tuveri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2006.08.012_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1050-1738(02)00186-X","article-title":"Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis","volume":"12","author":"Vincent","year":"2002","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.vph.2006.08.012_bib40","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1073\/pnas.122109599","article-title":"Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)","volume":"99","author":"Visconti","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2006.08.012_bib41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tcm.2004.09.001","article-title":"Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials","volume":"14","author":"Yla-Herttuala","year":"2004","journal-title":"Trends Cardiovasc. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189106001753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189106001753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T20:45:23Z","timestamp":1555793123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189106001753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1537189106001753"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2006.08.012","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}